Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
Shanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.
How this was made
The 30-second read
Why it matters
The failure undermines confidence in the drug's market potential, likely depressing both companies' shares.
Market read
Primary clinical trial news with immediate price impact on both the US partner and its Chinese collaborator.
What to watch
The trial's p‑value (0.0654) is close to significance; further data could alter the outlook.
Background
The article reports a failed late‑stage lung‑cancer trial by Arrivent Biopharma, causing a sharp sell‑off in its Chinese partner Shanghai Allist.
Ticker impact
Arrivent Biopharma reported its Phase 3 FURVENT trial failed to meet the primary endpoint, triggering a 20% drop in Shanghai Allist shares.
downward pressure as the market prices in the failed trial data
The trial failure is a primary disclosure with material clinical implications, and the partner's stock typically reacts to such outcomes.
Market effects
Biotech sector may see broader risk aversion toward EGFR‑targeted therapies.
Chinese biotech stocks could face sell pressure following the partner's trial failure.
Investors worldwide monitor trial outcomes for pipeline valuation.
Counterpoint
If the drug shows secondary benefits, some investors may view the miss as a buying opportunity at lower valuations.
Key entities
- companyArrivent Biopharma
US biotech partner reporting the trial failure.
- companyShanghai Allist Pharmaceuticals
Chinese biotech whose shares fell 20% after the partner's trial miss.
